Biotech - Cell Therapy
•100 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (100)
| Company | Market Cap | Price |
|---|---|---|
|
JNJ
Johnson & Johnson
CARVYKTI is a CAR-T cell therapy, placing it in the cell therapy/biotech space.
|
$591.00B |
$245.28
-0.60%
|
|
MRK
Merck & Co., Inc.
Strategic investments in cell therapy capabilities reflect the company's foray into autologous/allogeneic cell therapies.
|
$298.54B |
$120.29
+0.38%
|
|
GILD
Gilead Sciences, Inc.
Gilead's Kite CAR-T therapies (Yescarta, Tecartus) and Anito-cel represent cell therapy offerings.
|
$183.89B |
$148.23
+0.27%
|
|
BMY
Bristol-Myers Squibb Company
Breyanzi and Abecma are cell therapies, placing Cell Therapy as a direct product category.
|
$126.89B |
$62.31
+1.78%
|
|
VRTX
Vertex Pharmaceuticals Incorporated
VX-880 is an allogeneic stem cell-derived therapy, placing Vertex in the cell therapy category.
|
$121.25B |
$477.84
+0.75%
|
|
IBRX
ImmunityBio, Inc.
Cell therapy platforms including t-haNK / CAR-NK derivatives.
|
$8.86B |
$8.98
-10.20%
|
|
ACLX
Arcellx, Inc.
Company's lead products are CAR-T cell therapies within oncology; direct product category is cell therapy.
|
$6.61B |
$114.30
+0.21%
|
|
CRSP
CRISPR Therapeutics AG
CRISPR Therapeutics' CAR-T programs (CTX112, CTX131) represent cell therapy products (autologous/allogeneic formats).
|
$5.72B |
$59.99
+3.33%
|
|
TGTX
TG Therapeutics, Inc.
Azer-cel is TG's allogeneic CD19 CAR T-cell therapy program, representing a cell-therapy modality in its pipeline.
|
$4.63B |
$29.20
+1.13%
|
|
LEGN
Legend Biotech Corporation
CARVYKTI is a CAR-T cell therapy and Legend Biotech's flagship product, representing its direct cell-therapy manufacturing and commercialization activity.
|
$3.29B |
$17.84
-0.08%
|
|
BEAM
Beam Therapeutics Inc.
BEAM-101 is an autologous cell therapy (HSC-based) targeting sickle cell disease, fitting the cell therapy category.
|
$2.78B |
$27.50
+1.01%
|
|
ADPT
Adaptive Biotechnologies Corporation
Biotech - Cell Therapy tag reflects Immune Medicine's cell therapy exploration (Genentech collaboration).
|
$2.51B |
$16.44
+2.24%
|
|
GLPG
Galapagos N.V.
Core product category: CAR-T and other cell therapies (cell therapy platform).
|
$2.22B |
$33.72
+2.03%
|
|
MESO
Mesoblast Limited
Direct product category: allogeneic mesenchymal lineage cell therapy platform and approved product Ryoncil.
|
$1.87B |
$14.57
+0.14%
|
|
VCEL
Vericel Corporation
Vericel's core offerings are autologous cell therapies (MACI and Epicel), placing the company in the cell therapy space.
|
$1.77B |
$34.91
+1.51%
|
|
IOVA
Iovance Biotherapeutics, Inc.
Company's core offering is cell therapy (TIL) with autologous lymphocytes, including next-generation pipeline programs, defining the Biotech - Cell Therapy category.
|
$1.69B |
$4.25
+13.48%
|
|
IMTX
Immatics N.V.
Core product platform: TCR-engineered cell therapies (ACT) for solid tumors.
|
$1.24B |
$10.19
+3.56%
|
|
CAPR
Capricor Therapeutics, Inc.
Capricor's lead asset deramiocel is a cell-based therapy, the core product offering of the company.
|
$1.17B |
$25.51
-1.28%
|
|
PGEN
Precigen, Inc.
UltraCAR-T platform is a cell therapy platform, qualifying as Biotech - Cell Therapy.
|
$1.06B |
$3.56
+5.48%
|
|
SANA
Sana Biotechnology, Inc.
Sana's lead platform is HIP-modified cell therapy (ex vivo) for allogeneic cell transplantation.
|
$1.02B |
$3.80
-3.31%
|
|
PRME
Prime Medicine, Inc.
Engages in cell therapy programs (Prime Edited CAR-T) via collaborations, representing a core cell-based therapeutic modality.
|
$743.70M |
$4.12
-2.60%
|
|
PROK
ProKidney Corp.
Core product is rilparencel (REACT), an autologous cell therapy for preserving kidney function in CKD, fitting the Biotech - Cell Therapy category.
|
$656.25M |
$2.23
-0.22%
|
|
OCGN
Ocugen, Inc.
NeoCart is a regenerative medicine program, a cell therapy approach.
|
$572.92M |
$1.97
+5.65%
|
|
ALLO
Allogene Therapeutics, Inc.
Direct product category: off-the-shelf allogeneic CAR-T cell therapies (Allogene's core platform and pipeline).
|
$561.36M |
$2.54
+0.40%
|
|
RCKT
Rocket Pharmaceuticals, Inc.
Ex vivo cell therapy approach (LV-modified patient cells) qualifies as cell therapy.
|
$521.63M |
$4.82
+0.42%
|
|
LYEL
Lyell Immunopharma, Inc.
Lyell’s lead program LYL314 is a CAR-T cell therapy product targeting cancer (CD19/CD20 dual-target), the core business.
|
$457.23M |
$23.89
+2.40%
|
|
LCTX
Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics' core business is developing allogeneic cell therapy platforms and products (OpRegen, OPC1, ReSonance ANP1).
|
$445.29M |
$1.95
+3.17%
|
|
AUTL
Autolus Therapeutics plc
Core product: obe-cel CAR-T cell therapy (cell therapy) for rr B-ALL.
|
$433.81M |
$1.64
+0.93%
|
|
ORGO
Organogenesis Holdings Inc.
ReNu knee osteoarthritis program is a cell therapy (biotech) product, aligning with Biotech - Cell Therapy.
|
$364.24M |
$2.87
-0.17%
|
|
KYTX
Kyverna Therapeutics, Inc.
KYTX's lead and pipeline CAR-T products (KYV-101, KYV-102, KYV-201) are autologous/allogeneic CD19 CAR-T cell therapies, a direct cell therapy product category.
|
$351.59M |
$7.80
-4.06%
|
|
NWBO
Northwest Biotherapeutics, Inc.
DCVax is a dendritic cell-based autologous cell therapy platform, matching Biotech - Cell Therapy.
|
$329.08M |
$0.23
|
|
CABA
Cabaletta Bio, Inc.
Core product category: CAR-T cell therapy platform (CARTA) and rese-cel directly produced by Cabaletta.
|
$313.73M |
$3.42
+5.38%
|
|
CLLS
Cellectis S.A.
Lead assets UCART22 and UCART20x22 are allogeneic cell therapies (CAR-T) directly developed and manufactured by the company.
|
$271.22M |
$3.77
+3.14%
|
|
ABEO
Abeona Therapeutics Inc.
ZEVASKYN is an autologous cell-based therapy (cell therapy) targeting RDEB wounds.
|
$260.49M |
$5.05
-0.49%
|
|
IMMX
Immix Biopharma, Inc.
Directly categorizes the company’s lead product as a CAR-T cell therapy (cell therapy).
|
$246.82M |
$8.58
+5.28%
|
|
TARA
Protara Therapeutics, Inc.
TARA-2.00 is a cell therapy platform, representing the company’s lead product modality.
|
$239.21M |
$6.22
+1.14%
|
|
STTK
Shattuck Labs, Inc.
GADLEN platform and gamma delta T cell–targeting approaches indicate involvement in Cell Therapy.
|
$226.58M |
$4.71
+11.35%
|
|
CRGX
CARGO Therapeutics, Inc. Common Stock
Pipeline includes cell-based therapies (autologous/allogeneic CAR-T), aligning with Biotech - Cell Therapy.
|
$206.13M |
$4.47
|
|
RNAC
Cartesian Therapeutics, Inc.
Lead platform is an autologous cell therapy using mRNA CAR-T, a direct cell-therapy product line.
|
$204.64M |
$7.87
+5.21%
|
|
NKTX
Nkarta, Inc.
Nkarta is developing allogeneic CAR NK cell therapy (NKX019) for autoimmune diseases, directly fitting the Cell Therapy product category.
|
$193.90M |
$2.73
+6.42%
|
|
HUMA
Humacyte, Inc.
ATEV platform relates to tissue engineering/cell therapy platforms; relevant biotech tag.
|
$182.13M |
$1.16
+8.41%
|
|
CRBU
Caribou Biosciences, Inc.
Lead programs CB-010 and CB-011 are allogeneic CAR-T cell therapies targeting hematologic malignancies.
|
$176.00M |
$1.85
-2.12%
|
|
MXCT
MaxCyte, Inc.
Biotech - Cell Therapy category aligns with MaxCyte's role enabling cell therapies via transfection and processing platforms.
|
$164.17M |
$1.55
+0.65%
|
|
RCEL
AVITA Medical, Inc.
RECELL/autologous cell suspension represents a cell-therapy platform within regenerative medicine.
|
$151.25M |
$4.96
+3.22%
|
|
ARTV
Artiva Biotherapeutics, Inc.
AlloNK AB-101 is an allogeneic NK cell therapy platform, constituting Artiva's core product line.
|
$133.36M |
$5.50
+0.46%
|
|
ATRA
Atara Biotherapeutics, Inc.
Atara focuses on tab-cel (Ebvallo), an allogeneic T-cell therapy.
|
$123.46M |
$17.70
+0.71%
|
|
FATE
Fate Therapeutics, Inc.
Fate's iPSC platform manufactures off-the-shelf, multiplexed engineered cell therapies (CAR-T/CAR-NK), a core cell therapy business.
|
$116.48M |
$1.01
|
|
IPSC
Century Therapeutics, Inc.
Directly develops iPSC-derived cell therapies (CAR-iT, CAR-iNK, Allo-Evasion-enabled products) and related platforms.
|
$112.31M |
$1.76
+35.38%
|
|
ANIX
Anixa Biosciences, Inc.
CER-T CAR-T therapy is a direct cell therapy product focused on oncology.
|
$95.79M |
$2.90
+2.47%
|
|
FBIO
Fortress Biotech, Inc.
Fortress’ portfolio includes cell therapy programs (Mustang Bio), putting the firm in the Cell Therapy category.
|
$92.24M |
$3.10
+1.47%
|
|
COYA
Coya Therapeutics, Inc.
COYA's autologous regulatory T cell therapy program (COYA 101) represents a direct cell therapy product line.
|
$89.65M |
$5.36
-0.09%
|
|
MCRB
Seres Therapeutics, Inc.
SER-155 is a cultivated live biotherapeutic product (cell therapy) comprising a defined bacterial consortium.
|
$79.93M |
$9.21
+4.66%
|
|
VOR
Vor Biopharma Inc.
Vor Biopharma is focused on engineered cell therapies (eHSCs) and trem-cel, a cell therapy product.
|
$79.24M |
$12.50
+3.05%
|
|
MGX
Metagenomi, Inc. Common Stock
Affini-T Therapeutics collaboration indicates a focus on ex vivo cell therapy applications enabled by MGX's gene editing toolbox.
|
$65.31M |
$1.78
+2.30%
|
|
COEP
Coeptis Therapeutics, Inc.
GEAR Cell Therapy Platform is a core cell therapy biotech asset.
|
$63.12M |
$11.88
-3.65%
|
|
TCRX
TScan Therapeutics, Inc.
Directly related to cell therapy products (TCR-T therapies) and platform-enabled manufacturing via ImmunoBank/T-Plex.
|
$60.15M |
$1.06
-4.05%
|
|
INKT
MiNK Therapeutics, Inc.
MiNK's lead product agenT-797 and pipeline comprise allogeneic, off-the-shelf iNKT cell therapies, a direct Cell Therapy business.
|
$49.35M |
$10.76
+1.13%
|
|
ACET
Adicet Bio, Inc.
Directly develops allogeneic cell therapies (gamma delta T cells) for autoimmune diseases and cancer as its primary product platform.
|
$39.39M |
$7.55
+7.62%
|
|
ATNM
Actinium Pharmaceuticals, Inc.
Iomab-ACT and related programs intersect with cell therapy workflows by enabling conditioning for CAR-T and other cell therapies.
|
$38.37M |
$1.23
+10.81%
|
|
TVGN
Tevogen Bio Holdings Inc.
ExacTcell off-the-shelf T cell therapies and the TVGN 489 program position Tevogen as a cell therapy biotech focused on oncology and infectious disease.
|
$36.63M |
$0.19
-24.83%
|
|
INMB
INmune Bio, Inc.
INKmune constitutes a cell therapy platform (NK cell priming) for cancer, a core product line.
|
$35.09M |
$1.32
-5.36%
|
|
PLUR
Pluri Inc.
Directly related to placenta-derived cell therapy products PLX-PAD/PLX-R18 and the company's 3D cell expansion platform used for cell therapies.
|
$33.04M |
$3.71
+5.10%
|
|
CELU
Celularity Inc.
Celularity's core products are allogeneic placental-derived cell therapies produced via the IMPACT platform.
|
$32.03M |
$1.15
-4.17%
|
|
EUDA
EUDA Health Holdings Limited
EUDA's core biotech activity is a stem cell platform and cell therapy development using iPSCs.
|
$29.25M |
$0.98
+21.11%
|
|
ENLV
Enlivex Therapeutics Ltd.
Allocetra is Enlivex's lead cell therapy platform, directly produced and administered as a therapeutic cell product.
|
$28.63M |
$1.20
+5.75%
|
|
CCEL
Cryo-Cell International, Inc.
Cryo-Cell's core business is private cord blood and cord tissue stem cell collection, processing, and long-term cryogenic storage, aligning with the Biotech - Cell Therapy investable theme.
|
$26.38M |
$3.27
-0.46%
|
|
CUE
Cue Biopharma, Inc.
The Immuno-STAT platform enables T-cell modulation and cell-based therapeutic approaches, mapping to Biotech - Cell Therapy.
|
$25.93M |
$0.33
+9.43%
|
|
SNTI
Senti Biosciences, Inc.
Operates in cell-based therapies (CAR-NK) platform, aligning with off-the-shelf cellular therapy capabilities.
|
$24.91M |
$0.95
+0.14%
|
|
BRNS
Barinthus Biotherapeutics plc
SNAP-TI and VTP programs rely on cell-based immunotherapies (cell therapy).
|
$24.43M |
$0.61
+1.83%
|
|
FBLG
FibroBiologics, Inc. Common Stock
Core business is fibroblast-based cell therapies (CYWC628, CYMS101, CybroCell) in regenerative medicine; directly matches Biotech - Cell Therapy.
|
$19.33M |
$0.38
-2.93%
|
|
MRKR
Marker Therapeutics, Inc.
Marker Therapeutics develops MAR-T cell therapies, a cell-based immunotherapy platform targeting cancer.
|
$19.15M |
$1.48
-6.33%
|
|
GNTA
Genenta Science S.p.A.
Temferon is a hematopoietic stem cell-based cell therapy.
|
$16.65M |
$0.95
+3.12%
|
|
CTXR
Citius Pharmaceuticals, Inc.
NoveCite is a stem cell therapy, categorized under cell therapy.
|
$15.36M |
$0.73
-3.71%
|
|
ADAP
Adaptimmune Therapeutics plc
Adaptimmune develops engineered T-cell therapies (cell therapy) for cancer, including TECELRA and lete-cel.
|
$14.58M |
$0.06
+2.91%
|
|
BLRX
BioLineRx Ltd.
Motixafortide's role in stem cell mobilization ties BioLineRx to cell therapy enablement platforms.
|
$13.32M |
$2.81
|
|
KAPA
Kairos Pharma, Ltd.
KROS 201 involves dendritic cell–based activation, representing a cell therapy approach.
|
$13.06M |
$0.63
+1.03%
|
|
GDTC
CytoMed Therapeutics Limited
Core business platform focuses on cell-based immunotherapies (gamma delta T cells, NK cells), aligning with Biotech - Cell Therapy.
|
$12.23M |
$1.03
-1.89%
|
|
BCDA
BioCardia, Inc.
CardiAMP and CardiALLO are BioCardia's direct cell-therapy programs (autologous and allogeneic) targeted for cardiovascular disease.
|
$8.41M |
$1.46
+0.34%
|
|
TSBX
Turnstone Biologics Corp.
Lead asset revolves around Selected TILs, a cell therapy platform for cancer.
|
$8.21M |
$0.35
|
|
LGVN
Longeveron Inc.
LGVN's lead candidate laromestrocel is a mesenchymal stem cell (MSC) therapy, directly aligning with Biotech - Cell Therapy.
|
$7.96M |
$0.54
-3.94%
|
|
INAB
IN8bio, Inc.
INAB's core products are gamma-delta T cell therapies (INB-100, INB-200) and preclinical programs, a direct cell therapy offering.
|
$7.85M |
$1.76
+2.62%
|
|
BCTX
BriaCell Therapeutics Corp.
BriaCell develops off-the-shelf allogeneic cell therapies (Bria-IMT) and a cell-therapy platform (Bria-OTS).
|
$7.67M |
$4.13
+2.86%
|
|
CLGN
CollPlant Biotechnologies Ltd.
Tissue regeneration platforms can align with Cell Therapy-style biotech themes.
|
$7.22M |
$0.61
+7.64%
|
|
MBIO
Mustang Bio, Inc.
Develops cell therapy products, primarily CAR T therapies (cell-based immunotherapies).
|
$6.94M |
$0.98
+5.87%
|
|
PHIO
Phio Pharmaceuticals Corp.
Company pursues adoptive cell therapy (ACT) modalities and immune cell enhancement through INTASYL-based approaches.
|
$6.53M |
$1.14
+6.07%
|
|
ALZN
Alzamend Neuro, Inc.
ALZN002 employs autologous dendritic cell–based therapy, a cell therapy modality.
|
$6.22M |
$2.00
+6.12%
|
|
CELZ
Creative Medical Technology Holdings, Inc.
CELZ develops autologous/allogeneic cell therapies (ImmCelz and AlloStem), a core cell therapy business.
|
$4.80M |
$1.85
+3.93%
|
|
PMCB
PharmaCyte Biotech, Inc.
Cell-in-a-Box encapsulated cells constitute a direct cell-therapy product category.
|
$4.71M |
$0.70
-1.76%
|
|
BCLI
Brainstorm Cell Therapeutics Inc.
NurOwn is a proprietary autologous cell therapy platform developed by Brainstorm for ALS and related neurodegenerative indications, directly produced and administered by the company.
|
$4.24M |
$0.70
|
|
CLDI
Calidi Biotherapeutics, Inc.
The company uses stem cell-based delivery of oncolytic viruses (NeuroNova/SuperNova) as a core platform, aligning with Cell Therapy.
|
$3.77M |
$0.77
+4.55%
|
|
KALA
KALA BIO, Inc.
KPI-012 is a mesenchymal stem cell secretome (MSC-S) therapy, aligning with Biotech - Cell Therapy.
|
$2.67M |
$0.38
-5.27%
|
|
ERNA
Ernexa Therapeutics Inc.
Lead product is off-the-shelf allogeneic cell therapy using iPSC-derived mesenchymal stem cells (iMSCs).
|
$2.35M |
$0.31
+5.67%
|
|
CARM
Carisma Therapeutics, Inc.
CAR-Macrophage platform is a cell-therapy technology, directly representing Carisma's core product category.
|
$2.33M |
$0.15
+196.92%
|
|
AAGH
America Great Health
Joint venture and activities in cell therapy and regenerative medicine.
|
$2.12M |
$0.00
|
|
YBGJ
Yubo International Biotech Limited
Endometrial stem cell research and potential cell therapies (core biotech focus).
|
$1.77M |
$0.01
|
|
BRTX
BioRestorative Therapies, Inc.
BRTX-100 is an autologous mesenchymal stem cell therapy, the company's lead cell therapy product for disc disease.
|
$1.73M |
$0.22
+6.05%
|
|
HCWB
HCW Biologics Inc.
HCWB's CAR-T engagers and T-cell therapies place the company in Cell Therapy.
|
$1.18M |
$0.65
+18.18%
|
|
NLSP
NLS Pharmaceutics AG
Kadimastem's allogeneic cell-therapy platform (IsletRx, AstroRx) and NLSP's merger create a clear Cell Therapy business line.
|
$894150 |
$0.79
-72.35%
|
|
RGBP
Regen BioPharma, Inc.
Pipeline includes HemaXellarate, dCellVax, tCellVax, and DuroCAR, representing cell therapy modalities.
|
$224038 |
$0.01
|
|
CERO
CERo Therapeutics Holdings, Inc.
CER-T is a cell therapy platform with lead candidate CER-1236, indicating direct cell-based therapeutic products.
|
$14826 |
$0.10
+141.50%
|
Loading company comparison...
Loading industry trends...
Loading research report...
